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Grafts versus stents in 
multivessel disease
The result of a study recently published in JAMA 
Internal Medicine points out that recent trials of 
percutaneous coronary intervention (PCI) v. coronary 
artery bypass grafting (CABG) for multivessel disease were not 
designed to detect a difference in mortality. Consequently, the 
comparative effects of these two revascularisation methods on long-
term mortality are still unclear. In the absence of hard evidence for 
mortality difference, PCI is often preferred over CABG in these 
patients, given the less invasive nature of the former.
Sipahi et al. used a meta-analysis of all randomised clinical trials 
of the current era that compared the two treatment techniques in 
patients with multivessel disease to determine the comparative effects 
of CABG v. PCI on long-term mortality and morbidity. 
These included randomised trials with ≥1 arterial grafts 
used in at least 90% and ≥1 stents used in at least 70% of cases, 
reporting outcomes in patients with multivessel disease. The 
number of events at the longest possible follow-up time and the 
sample sizes were extracted.
Six randomised trials enrolling a total of 6 055 patients were 
included, with a weighted average follow-up time of 4.1 years. 
There was a significant reduction in total mortality with CABG 
compared with PCI. There were also significant reductions in 
myocardial infarction and repeat revascularisation procedures. A 
trend towards excess strokes with CABG was observed, but this 
was not statistically significant. 
In patients with multivessel coronary disease, CABG compared 
with PCI leads to an unequivocal reduction in long-term 
mortality and myocardial infarction and to a reduction in repeat 
revascularisations, regardless of whether patients are diabetics or 
not. These findings have implications for the management of such 
patients.
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Diabetes and ageing
There are, and will continue to be, larger populations 
of older adults with type 2 diabetes mellitus in nearly 
all countries. Consequently, it will be even more 
important to try to understand the clinical course of 
this disease in the elderly to establish evidence-based clinical practice 
recommendations, identify research priorities, allocate resources and 
set healthcare policies in those countries most affected. Huang et al. 
report on the ‘Diabetes and aging study’, recently published in JAMA 
Internal Medicine. 
They analysed contrasting rates of diabetes complications and 
mortality across age and diabetes duration categories using a 
cohort study (2004 - 2010) that included 72 310 older patients (≥60 
years) with type 2 diabetes mellitus enrolled in a large, integrated 
healthcare delivery system. Incidence densities (events per 1 000 
person-years) were calculated for three age categories (60 - 69, 70 - 
79, and ≥80 years) and duration of diabetes (shorter (0 - 9 years) v. 
longer (≥10 years)).
The main outcome measures were acute hyper- and hypoglycaemic events, 
microvascular complications (end-stage renal disease, peripheral vascular 
disease, lower limb amputation, and diabetic eye disease), cardiovascular 
complications (coronary artery disease, cerebrovascular disease, and 
congestive heart failure), and all-cause mortality.
They found that among older adults with diabetes of short 
duration, cardiovascular complications followed by hypoglycaemia 
were the most common non-fatal complications. For example, among 
individuals aged 70 - 79 years with a short duration of diabetes, 
coronary artery disease and hypoglycaemia rates were higher 
compared with end-stage renal disease, lower limb amputation, and 
acute hyperglycaemic events. A similar pattern among patients in the 
same age group with a long duration of diabetes, with some of the 
highest incidence rates of coronary artery disease and hypoglycaemia 
(18.98 per 1 000 person-years and 15.88 per 1 000 person-years, 
respectively) compared with end-stage renal disease (7.64 per 1 000 
person-years), lower limb amputation (4.26 per 1 000 person-years), 
and acute hyperglycaemic events (1.76 per 1 000 person-years), was 
found. For a given age group, the rates of each outcome, particularly 
hypoglycaemia and microvascular complications, increased 
dramatically with longer duration of the disease. However, for a 
given duration of diabetes, rates of hypoglycaemia, cardiovascular 
complications, and mortality increased steeply with advancing age, 
and rates of microvascular complications remained stable or declined.
The conclusion is that duration of diabetes and advancing age 
independently predict diabetes morbidity and mortality rates. As long-
term survival with diabetes increases and the population ages, more 
research and public health efforts to reduce hypoglycaemia will be 
needed to complement ongoing efforts to reduce cardiovascular and 
microvascular complications.
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